Yoshihisa Shimada
Overview
Explore the profile of Yoshihisa Shimada including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
162
Citations
1626
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nagase W, Kudo Y, Matubayashi J, Amemiya R, Tanigawa M, Shimada Y, et al.
Cureus
. 2025 Mar;
17(2):e78638.
PMID: 40062044
Ectopic mediastinal parathyroid adenoma is rare and is generally managed by surgical resection as a definitive treatment. Intraoperative parathyroid hormone (ioPTH) monitoring is valuable for ensuring the complete removal of...
2.
Nagase W, Kudo Y, Matsubayashi J, Takahashi S, Murakami K, Furumoto H, et al.
Eur J Surg Oncol
. 2025 Jan;
51(3):109565.
PMID: 39874612
Objective: Pulmonary pleomorphic carcinoma is a relatively rare and aggressive subtype of non-small cell lung cancer (NSCLC), with a poor prognosis and early recurrence, and is resistant to conventional therapies....
3.
Shimada Y
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682272
Despite the introduction of effective systemic therapies and advancements in precision medicine, recurrence or progression remains common in advanced non-small cell lung cancer (NSCLC). For a subset of patients with...
4.
Lin C, Lin K, Lin X, Yuan H, Zhang Y, Xie Z, et al.
Transl Lung Cancer Res
. 2024 Nov;
13(10):2713-2728.
PMID: 39507021
Background: Lung adenocarcinoma (LUAD) is one of the most prevalent types of lung cancer (LC), accounting for 50% of all LC cases. Despite therapeutic advancements, patients suffer from adverse drug...
5.
Aokage K, Koyama S, Kumagai S, Nomura K, Shimada Y, Yoh K, et al.
Clin Cancer Res
. 2024 Oct;
30(24):5584-5592.
PMID: 39453771
Purpose: Angiogenesis inhibitors are known to modify tumor immunity. Combination of angiogenesis inhibitors with immune checkpoint inhibitors has shown efficacy against many types of cancers, including non-small cell lung cancer...
6.
Shimada Y, Ohira T, Ikeda N
Mediastinum
. 2024 Aug;
8:42.
PMID: 39161581
Background And Objective: Thymic epithelial tumors (TETs), including thymomas and thymic cancers, are relatively rare malignancies originating from the thymus. Although complete surgical resection is the cornerstone of treatment for...
7.
Kudo Y, Nakamura T, Matsubayashi J, Ichinose A, Goto Y, Amemiya R, et al.
Clin Lung Cancer
. 2024 May;
25(5):431-439.
PMID: 38760224
Objectives: Distinguishing solid nodules from nodules with ground-glass lesions in lung cancer is a critical diagnostic challenge, especially for tumors ≤2 cm. Human assessment of these nodules is associated with...
8.
Hayakawa K, Irisawa R, Umefune R, Mae K, Shimada Y, Takahashi R, et al.
J Dermatol
. 2024 Apr;
51(9):e306-e307.
PMID: 38605458
No abstract available.
9.
Zhang H, Chen L, Mao F, Li J, Hamaji M, Shimada Y, et al.
J Thorac Dis
. 2024 Mar;
16(2):1450-1462.
PMID: 38505060
Background: Bilateral synchronous multiple primary lung cancer (BSMPLC) presents significant clinical challenges due to its unique characteristics and prognosis. Understanding the risk factors that influence overall survival (OS) and recurrence-free...
10.
Mimae T, Miyata Y, Tsubokawa N, Shimada Y, Nagashima T, Ito H, et al.
Ann Thorac Surg
. 2024 Jan;
118(2):395-401.
PMID: 38199462
Background: Lobectomy is a standard surgical procedure for peripherally located early-stage non-small cell lung cancers (NSCLCs) measuring 2 to 4 cm. However, it is unclear whether sublobar resections, such as...